A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06777316

Public ClinicalTrials.gov record NCT06777316. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

Study identification

NCT ID: NCT06777316
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Cogent Biosciences, Inc.; Industry
Enrollment: 110 participants

Conditions and interventions

Conditions

Interventions

CGT4859 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 22, 2025 (Actual)
Primary completion: Mar 2027 (Estimated)
Completion: Jun 2027 (Estimated)
Last update posted: Apr 17, 2026

2025 – 2027

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Stanford Cancer Institute	Palo Alto	California	94305	—
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	—
Moffitt Cancer Center	Tampa	Florida	33612	—
University of Chicago Medicine Comprehensive Cancer Center	Chicago	Illinois	60637	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Mayo Clinic Rochester	Rochester	Minnesota	55905	—
The Christ Hospital	Cincinnati	Ohio	45219	—
Taussig Cancer Center - Cleveland Clinic	Cleveland	Ohio	44195	—
Fox Chase cancer Center	Philadelphia	Pennsylvania	19111	—
Tennessee Oncology	Nashville	Tennessee	37203	—
MD Anderson Cancer Center	Houston	Texas	77030	—
Huntsman Cancer Institute - University of Utah	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06777316, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 17, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06777316 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →